KLK3 and Familial prostate cancer: This paper investigated whether the standardisation of information submitted to an endpoint committee for UCD ascertainment in the ongoing Cluster randomised triAl of PSA testing for Prostate cancer (CAP) (ISRCTN92187251) successfully reduced the ability of reviewers in correctly guessing the trial arm, thereby minimising any potential biases arising from such guesses.